Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Lung Cancer Pharmacogenomics

  • Niki Karachaliou
  • Rafael Rosell
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_7207-1



Lung cancer is the most frequently diagnosed cancer and a leading cause of cancer mortality worldwide. For therapeutic purposes, lung cancer is divided into two classes, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The three main subtypes of NSCLC are adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma with adenocarcinoma being the most common histological subtype. Lung cancer pharmacogenomics is the study of the role of lung cancer genetics in drug response. Pharmacogenomics encompasses a genome-wide association approach, incorporates genomics and epigenetics, and deals with the effects of multiple genes on drug response. The aim of lung cancer pharmacogenomics is to develop means to optimize lung cancer therapy with respect to the genotype of the patient, ensuring maximum efficacy and minimal adverse effects. Deeper understanding of the...


Anaplastic Lymphoma Kinase Advanced NSCLC EGFR Mutation Anaplastic Lymphoma Kinase Inhibitor Anaplastic Lymphoma Kinase Fusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Karachaliou N, Rosell R (2014) Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. Cancer Biol Med 11:173–181PubMedPubMedCentralGoogle Scholar
  2. Karachaliou N, Rosell R, Morales-Espinosa D, Viteri S (2014) Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. Expert Rev Anticancer Ther 14:807–815PubMedCrossRefGoogle Scholar
  3. Karachaliou N, Rosell R, Carcereny E (2015) How to personalize chemotherapy in stage IV NSCLC? In: New therapeutic strategies in lung cancers, pp 119–129. Springer International Publishing: SwitzerlandGoogle Scholar
  4. Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C et al (2014) Two biomarker-directed randomized trials in European and Chinese patients with non-small-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann Oncol Off J Eur Soc Med Oncol ESMO 25(11):2147–55Google Scholar
  5. Rosell R Dynamic evolution of ALK positive non-small cell lung cancers and management of associated brain metastases [podcast]. J Clin Oncol. January 26, 2015. doi:10.1200/JCO.2011.55.5555Google Scholar
  6. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246PubMedCrossRefGoogle Scholar
  7. Rosell R, Bivona TG, Karachaliou N (2013) Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382:720–731PubMedCrossRefGoogle Scholar
  8. Rosell R, Karachaliou N, Wolf J, Ou SH (2014) ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. Lancet Respir Med 2:966–968PubMedCrossRefGoogle Scholar

See Also

  1. (2012) Targeted therapy. In: Schwab M (ed) Encyclopedia of cancer. Springer, Berlin/Heidelberg, p 3610. doi:10.1007/978-3-642-16483-5_5677Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Instituto Oncológico Dr. RosellQuiron-Dexeus University HospitalBarcelonaSpain
  2. 2.Pangaea BiotechBarcelonaSpain
  3. 3.Cancer Biology and Precision Medicine ProgramCatalan Institute of Oncology, Hospital Germans Trias i PujolBadalonaSpain
  4. 4.Molecular Oncology Research (MORe) FoundationBarcelonaSpain